Lobe Sciences closes non-brokered private placement of 24,705,880 shares at $0.085 each for $2.1 million

• Lobe Sciences closed a non-brokered private placement of 24,705,880 common shares at $0.09 per share.
• Gross proceeds totaled about $2.1 million.
• Proceeds earmarked for working capital, general corporate purposes, progress on S-100 for sickle cell disease.
• Part of the funds to support subsidiary Applied Lipid Technologies’ work to advance S-100 toward human trials.
• Shares were sold in an unregistered offering under the U.S. Securities Act of 1933.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lobe Sciences Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608200800ACCESSWRNAPR_____1209673) on August 20, 2026, and is solely responsible for the information contained therein.